Precision medicine driven by cancer systems biology
- 5.4k Downloads
Molecular insights from genome and systems biology are influencing how cancer is diagnosed and treated. We critically evaluate big data challenges in precision medicine. The melanoma research community has identified distinct subtypes involving chronic sun-induced damage and the mitogen-activated protein kinase driver pathway. In addition, despite low mutation burden, non-genomic mitogen-activated protein kinase melanoma drivers are found in membrane receptors, metabolism, or epigenetic signaling with the ability to bypass central mitogen-activated protein kinase molecules and activating a similar program of mitogenic effectors. Mutation hotspots, structural modeling, UV signature, and genomic as well as non-genomic mechanisms of disease initiation and progression are taken into consideration to identify resistance mutations and novel drug targets. A comprehensive precision medicine profile of a malignant melanoma patient illustrates future rational drug targeting strategies. Network analysis emphasizes an important role of epigenetic and metabolic master regulators in oncogenesis. Co-occurrence of driver mutations in signaling, metabolic, and epigenetic factors highlights how cumulative alterations of our genomes and epigenomes progressively lead to uncontrolled cell proliferation. Precision insights have the ability to identify independent molecular pathways suitable for drug targeting. Synergistic treatment combinations of orthogonal modalities including immunotherapy, mitogen-activated protein kinase inhibitors, epigenetic inhibitors, and metabolic inhibitors have the potential to overcome immune evasion, side effects, and drug resistance.
KeywordsCancer systems biology Melanoma Subtype Cancer metabolism Oncometabolite Epigenomics CSD SCNA Driver Big data Precision medicine Personalized medicine Neoantigen Immunotherapy Combination therapy PD1 PDL1 CTLA4 BRAF MEK SWI/SNF ARID1A ARID2 PRC2 EZH2
1 The impact of genomics and systems biology on precision medicine
Definitions of terminology in precision medicine, genome sequencing, and cancer systems biology
Medical model tailored to the individual patient. Integrates research knowledge from biomarkers and genomic profiles to accomplish quick, efficient, and accurate medical predictions and decisions.
Data sets outsize traditional data management and processing. Scale, complexity, and dynamics require new architecture, techniques, algorithms, and analytics to manage it and extract value from it. Big data can be identified by V-type characteristics (see Table 1). Big data analysis can reveal trends, patterns, and correlations based on network interactions.
Study of all genes in the human genome. Genomics aims at a full collection of genes and mutations, both inherited and somatic that contribute to the development of an organism, as well as its normal homeostatic function or diseased states. Genome is a portmanteau of the words gene and chromosome.
Chemical modifications that do not change the DNA sequence but can affect gene activity. Epigenomics refers to capturing epigenetic marks on a genome-wide scale, such as DNA methylation and post-translational modifications of histone chromatin, while epigenetics focuses on regulatory factors and reversible processes affecting gene expression, non-genomic inheritance, and phenotypes that are not the result of variations in DNA sequence.
Science of quantifying, modeling, and visualizing network interactions. Once a model is formulated, systems biology cycles between testable hypotheses and experimental validation.
Collection of methods to sequence an entire genome in a single run. The technology involves the capture of fragmented genomic DNA by oligonucleotide probes that collectively cover all exonic or whole genomic sequence regions (abbreviated as WES or WGS, respectively).
The process of determining the genetic makeup of an individual. This can include an entire genome or be targeted to regions associated with a clinical phenotype.
Variation at a single position in a DNA sequence among individuals or chromosomes. If more than 1% of a population does not carry the same nucleotide at a specific position in the DNA sequence, then this variation can be classified as a single-nucleotide polymorphism, abbreviated SNP and pronounced as snip. SNPs are not just associated with genes or diseases; they can also occur in non-annotated regions of DNA.
Somatic copy number alterations, abbreviated SCNAs, are multiplications of deletions of chromosome arms of focal regions that have arisen in a non-germline tissue for example just in a tumor. In contrast, copy number variations, abbreviated CNVs, originate from changes in germline cells and are thus in all cells of the organism.
Rate-limiting step positioned at top of hierarchy. Topologically, master regulators are found at branch points of networks influencing metabolic flux or signaling pathways related to cellular decisions on proliferation, survival, or differentiation.
Chain of signaling molecules that communicates a signal from a cell surface receptor into the nucleus of the cell to control a gene expression program including proliferation, mitosis, differentiation, and cell survival. A mitogen-activated protein kinase, abbreviated as MAP kinase or MAPK is part of a kinase family specific to phosphorylation of amino acids serine, threonine, and tyrosine. MAPKs are operated as switches in an amplifying cascade, where phosphorylation of one kinase results in activation of the next kinase. Oncogenic mutations can result in constitutively activated kinases, thereby triggering uncontrolled cell proliferation. Major pathway that is dysregulated in malignant melanoma.
Engages certain parts of a person’s immune system to fight diseases such as cancer. This can be accomplished by antibodies, vaccines, or stimulation of the immune system. Immune evasion is a hiding mechanism of cancer cells, which manage to downregulate surface markers that can be recognized by the immune system thereby facilitating unmonitored survival. T-cell immune checkpoint inhibitors silence control elements of the immune system and result in enhanced immune recognition and attack of cancer cells.
Newly formed epitope that has not been previously recognized by the immune system. New epitopes can arise as a consequence of tumor-specific mutations. Based on such epitopes, the immune system can respond or suppress tumor-reactive T-cell populations, thereby playing a major factor in the activity of immunotherapies such as T-cell checkpoint blockade and adoptive T-cell therapy.
Small molecule whose accumulation leads to cancer initiation and progression by metabolic and signaling dysregulation. Specific enantiomers of hydroxy-keto acids or amino acids are accumulated as a result of defective enzymes in cancer and cause genome-wide changes of gene expression by acting as inhibitors of regulatory proteins.
Big data challenges in precision medicine and cancer systems biology
Big data characteristic
Big data challenges in precision medicine and cancer systems biology
Complementary omics platforms generate terabytes of raw data for each patient to be processed, analyzed, and interpreted.
Data in motion
Necessity to acquire, process, share, stream, and compare data; otherwise, important clinical decisions or milestones may be missed.
Data in different forms
Data in different formats and from different sources covers all levels of biological information from genomics, epigenomics, transcriptomics, proteomics, metabolomics, fluxomics, and phenomics.
Data with uncertainty
Sample quality, heterogeneity, efficiency of alignment, data compatibility, incompleteness, ambiguities, latency, deception, and model approximations are factors contributing to uncertainty in data evaluation.
The origin of malignant melanoma—similar to other cancers—is found in cumulative alterations of our genomes and epigenomes progressively leading to uncontrolled cell proliferation. By disrupting signals controlling cell division and migration, such alterations may eventually lead to invasive malignancies able to metastasize and populate distant sites. The molecular signatures of genomic and epigenomic changes will provide insight as to why melanoma stands out as such a serious and aggressive malignancy. Furthermore, this knowledge will impact our perspective on how to approach melanoma prevention, diagnosis, and therapy. We will provide examples of how systems biology- and genome biology-driven approaches to cancer accelerate our ability to understand and respond to malignant melanoma.
2 Melanoma genomics and big data challenges in precision medicine
The range of observed mutation rates within and across tumor types spans more than five orders of magnitude (between 0.03 and 7000/Mbp) . Melanoma was one of the earliest tumor types sequenced, contributing to the forefront of cancer genomics. The first comprehensive catalog of somatic events was established by WGS on the metastatic COLO-829 cell line derived from a malignant melanoma patient . Cancer genomics experienced a peak in 2012 (Fig. 2a), when many studies from The Cancer Genome Atlas (TCGA) matured, publically funded by the National Cancer Institute [16, 17, 18]. In a collaborative effort, thousands of tumor biopsies were deposited in bio-specimen repositories, sequenced, processed at individual data levels, merged, and analyzed. Similarly, the number of melanoma genomes sequenced broke the hundreds in the same year [19, 20, 21, 22]. However, the ability of melanoma genomics to keep up with the pace and trends in other cancer genomics fields was temporarily hampered by the disproportionate data demands and frequent somatic mutation calls (Fig. 2b, Box 1). In fact, the TCGA skin cutaneous melanoma (SKCM) studies of 2015 required more somatic mutation calls (average rate of 18/Mbp; many individual specimens with rates above 1000/Mbp) than all other TCGA genomics studies combined [13, 23] (Fig. 2c). The bioinformatics tool Introns Vs Exons (InVEx) , designed to identify driver genes by taking the specific background mutation rate per patient and per gene into consideration, is currently the gold standard in melanoma genomics. Genome-wide capture of significant somatic events in melanoma is computationally intensive. Currently, more than 700 melanoma specimens with WES are available, comprising about 4% of the overall cancer genomics efforts (Fig. 2a). Given the current 1.6-fold increase in data production and exomes sequenced per year, it is expected that soon cancer studies across all tissues can accomplish 10,000s and melanoma studies 1000s of specimens/year. Sharable data formats like oncotator will facilitate future meta-studies of public and private melanoma genomics efforts . According to the saturation analysis of cancer drivers, it will take more than 5000 specimens to reach more than 99% power for a comprehensive catalog of cancer drivers with intermediate mutation frequencies of 2–5% in melanoma [14, 25]. Despite that the search for melanoma driver genes is not saturated, the cancer research community has already established a consistent set of high-frequency driver genes.
A successful approach to melanoma precision medicine will take an integrated, seamless team effort of clinicians, researchers, and providers (Fig. 1a). While genetic insights are quickly adopted into the clinical decision-making process, the infrastructure for genomics and precision medicine yet has to be established. Deep sequencing efforts of melanoma specimens are not well-integrated into the clinical routine, and cohort-based genomics tools like GISTIC , MutSigCV , or InVEx  are rather built for discovery research  rather than day-to-day diagnostics. Patient consented data sharing is necessary to securely exchange data between clinical caretakers, biobanks, omics data acquisition platforms, cloud-based processing, and genomics researchers. Not surprisingly, conservative models of privacy were challenged long before the advent of precision medicine by direct-to-consumer genetic tests and population genome research projects [28, 29, 30, 31]. Instead of relying on generalizable knowledge, tomorrow’s repositories are moving towards fully consented models motivated by a main benefit of being able to associate longitudinal health records [32, 33, 34] (Fig. 1). A first step, the rebranding of personalized medicine to precision medicine, has been successfully undertaken and resulted in broad public approval in contrast to the early rhetoric of personalized medicine . Genomic and epigenomic testing will be a useful tool to increase therapeutic success rates. Genetic markers hold a well-defined probabilistic value, but when it comes down to it, clinical implementation is important to address ethical boundaries including stigmata of genetic determinism. Reexamination and an update of ethical standards to catch up with rapidly evolving innovations in precision medicine, forensics, and population genomics seem inevitable.
Early on, identification of activating point mutations in the mitogen-activated protein kinase (MAPK) pathway in B-Raf proto-oncogene (BRAF, serine/threonine kinase, Gene ID: 673) [36, 37] and neuroblastoma RAS viral oncogene homolog (NRAS, Gene ID: 4893) made it possible to match genotyped kinase mutations with precision medicine approaches based on specific kinase inhibitors [38, 39]. Although BRAF-activated melanomas initially have been the most successful melanoma subset due to targeted therapies, they will ultimately develop resistance and there is rapid progress in complementary approaches especially ones taking advantage of the immune system to fight cancer cells. In principle, melanoma can be targeted from complementary angles, including immune-checkpoint inhibitors (IMMUNOi) and/or targeted therapy with inhibitors of specific signaling pathways such as the mitogen-activated protein kinase inhibitors (MAPKi), epigenetic inhibitors (EPIi), or metabolic inhibitors (METABi) (Fig. 1c).
The survival of advanced metastatic melanoma patients has dramatically improved due to second-generation clinical trials of melanoma drugs involving regimes with targeted therapy or immune-checkpoint antibodies. For both groups, combinations proved to be superior to single-agent regimens: Inhibition of BRAF in combination with mitogen-activated protein kinase kinase 7 (MAP2K7, MEK, Gene ID: 5609) improved survival compared to single MAPKi [40, 41, 42, 43]; blockade of combined immune checkpoints by humanized antibodies improved survival compared to single IMMUNOi of cytotoxic T-lymphocyte associated protein 4 (CTLA4, Gene ID: 1493) with programmed cell death 1 (PDCD1, PD1, CD279, Gene ID: 5133) or CD274 molecule (CD274, PDL1, PDCD1L1, Gene ID: 29126) [44, 45, 46, 47, 48] (Table 2).
Specific small-molecule agents and respective trials include BRAF MAPKi: vemurafenib (PLX4032), dabrafenib (GSK2118436), and encorafenib (LGX818) [38, 49, 50, 51]; MAP2K7 (MEK) MAPKi: trametinib (GSK-1120212) and cobimetinib (GDC-0973) ; combination of BRAF and MAP2K7 MAPKi [40, 41, 42, 43, 52, 53, 54]; CTLA4 IMMUNOi: ipilimumab (MDX-010) and tremelimumab (CP-675206), [55, 56, 57, 58, 59]; PDCD1 (PD1) IMMUNOi: nivolumab (MDX-1106, Opdivo) and pembrolizumab (MK-3475, Keytruda) ; CD274 (PDL1) IMMUNOi: atezolizumab (Tecentriq); and combinations of PDCD1 and CTLA4 IMMUNOi [44, 45, 46, 61].
Clinical trials with single-agent regimens or combinations of melanoma MAPKi and IMMUNOi drugs
Combination of BRAF and MEK inhibition
Combination of PDCD1 and CTLA4 blockage
Because relapse, disease progression, or high rates of autoimmune toxicity still need to be overcome, precision medicine in cancer offers hope for better long-term benefits and reduced side effects. While the clinical relevance of immune cells in the control of human cancers is well established and genome sequencing captures the somatic landscape, neoantigens that arise as a consequence of tumor-specific mutations are a major factor in the activity of immunotherapies [64, 65, 66, 67, 68, 69, 70, 71, 72, 73]. Further, neoantigens present themselves as targets for personalized vaccines and cell therapies that target patient-specific cancer mutations [74, 75, 76, 77, 78, 79]. The identification of neoantigens can be assisted by structure-based prediction or modeling approaches . Predictions of drug responses in melanoma will eventually improve by looking into gene expression signatures associated with immune sensitivity or resistance .
3 Precision medicine profile of malignant melanoma patient with BRAF, EZH2, and ARID signature
4 Tumor suppressors and chromatin remodeling complexes carry protective function but impede simple genotyping
Non-coding, non-sense mutations are of particular importance in tumor suppressors, since such factors carry gatekeeping and protective function in healthy tissue. In melanoma, highest ranking tumor suppressor genes are tumor protein p53 (TP53, Gene ID: 7157), neurofibromin 1 (NF1, Gene ID: 4763), AT-rich interaction domain 2 (ARID2, BAF200, Gene ID: 196528), AT-rich interaction domain 1A (ARID1A, BAF250, Gene ID: 8289), cyclin-dependent kinase inhibitor 2A (CDKN2A, P14ARF/P16INK4A, Gene ID: 1029), and phosphatase and tensin homolog (PTEN, Gene ID: 5728). In contrast to oncogenic gain-of-function events, deleterious loss-of-function events of tumor suppressors are usually homozygous but diverse in their molecular profile. The ATP-fueled chromatin remodeling complex switch/sucrose non-fermentable (SWI/SNF) [94, 95] around ARID1A and ARID2 has the ability to make chromatin accessible for gene expression and for repair enzymes counteracting UV-induced DNA damage. Similar to PRC2, the SWI/SNF complex is essential for the self-renewal in melanocyte development and in pluripotent stem cells. A diverse array of somatic copy number deletions and non-sense mutations of epigenetic regulators ARID1A and ARID2 lead to dysfunctional chromatin remodeling (Fig. 3d). Such unprecedented complexity of the mutational landscape of cancer drivers puts simple targeted, single-nucleotide variation-based genotyping assays at a disadvantage. In contrast, genome sequencing has the ability to capture both breadth and depth of somatic alterations in cancer. However, calling of SCNAs and somatic mutations for each patient is just a fraction of the precision medicine workflow. Only in few rare cases of well-characterized genomic alterations it is possible to reliably predict implications at the messenger, protein, and metabolite levels. For effective precision medicine treatment, systems biology interpretation, comparison to human mutation, genomics, and variant databases [31, 96, 97, 98], functional connection between different omics platforms, and prediction for drug response are equally important  (Figs. 1b and 4a–d).
5 Oncometabolites connect melanoma metabolism and epigenetics
No field other than melanoma has better accounted for connections between genetic causation, disease phenotype, and physical presentation: genomic studies have the ability to identify links between pigmentation of skin, hair, and eyes, tissue development, melanogenesis, pigment metabolism, mitogenic signaling pathways, ethnicity, gender, age, susceptibility loci, disease risk, initiation, and melanoma progression (Fig. 4a). Profiling studies of melanoma utilizing metabolomics and fluxomics revealed a distinct decoupling of glycolysis and glutamine-fueled TCA cycle in support of hypoxic survival [100, 101, 102]. While metabolic rewiring supported by specific isoforms of metabolic enzymes including hexokinase, phosphoglycerate dehydrogenase, serine methyl transferase, glycine cleavage complex, pyruvate kinase, pyruvate dehydrogenase, oxoglutarate dehydrogenase, isocitrate dehydrogenase, pyrroline-5-carboxylate reductase, glutamic oxaloacetic transaminase, and glutaminase facilitate production of biosynthetic precursors, metabolites can also have functions in signaling and epigenetics [99, 103, 104] (Fig. 4a, b). Overabundance or limitation of onco-metabolites such as amino- and beta-ketoacids [105, 106, 107] are direct suppliers and controllers of histone methyl modifiers . Mutant isocitrate dehydrogenase (NADP(+)) 1 (IDH1, Gene ID: 3417) will produce 2-hydroxyglutarate (2HG, (R)-hydroxyglutarate, PubChem CID: 439391) and modulate histone lysine demethylases (KDMs) known to be central epigenetic regulators. In contrast, histone lysine methyltransferases (KMTs) like EZH2 rely on a steady supply of S-adenosyl methionine (SAM, PubChem CID: 9865604) utilized for histone tri-methylation leading to repression of tumor suppressors [85, 109]. The emphasis of EZH2 in melanoma is enhanced by specific loss of other KTMs .
6 Rational combination of orthogonally targeted therapies
The fraction of newly discovered epigenetic players in melanoma genomics is striking and indicates environmental implications beyond UV-induced carcinogenic photoproducts . In contrast to genomics, the emerging field of epigenomics represents only about 2% of the genome-scale studies but grows at a much higher rate . The co-occurrence of BRAF and EZH2 hyperactivation [13, 85] as illustrated in the precision medicine case in melanoma presented above opens new possibilities for targeted treatment. Mono-therapy with MAPKi (either against BRAF or MAP2K7) is known to lead to drug resistance and disease progression. Combination therapies of different MAPKi molecules are effective but have significant side effects. A precision treatment that takes advantage of the independence of signaling and epigenetic pathways could combine MAPKi and EPIi (Fig. 4a). Elevated activity of EZH2 in cancer can be targeted by small-molecule drugs (e.g., GSK126, PubChem CID 68210102)  and is associated with sensitivity to apoptotic cell death . Transcriptomic profiling showed that several well-known tumor suppressors such as BCL2 family apoptosis regulator (BOK, BCL2L9L, Gene ID: 666), N-myc downstream regulated 1 (NDRG1, Gene ID: 10397), and Ras association domain family member 5 (RASSF5, Gene ID: 83593) are downregulated in cells with abnormalities in EZH2, which can be reversed by inhibitor treatment . An in vitro EZH2 drug targeting assay made it possible to validate genes associated with immune recognition, cytokine, chemokine, and major histocompatibility complex class II antigen presentation [85, 113]. Identified target genes by combination of transcriptomic and ChIP-Seq assessment revealed genes associated with tumor suppression, apoptosis, cell differentiation, cell cycle inhibition, and repression of metastases as well as antigen processing and presentation pathways. EZH2 controls cross-talk with natural killer cells suggesting an immunosuppressive effect of EZH2 involving both innate and adaptive immunity . Cell culture and animal models with EZH2 inhibitors show significantly decreased spheroid growths, cell cycle arrest, apoptosis, and tumor regression [85, 109, 114]. EZH2 enhances immune evasion and tumor proliferation by repressing a defined gene expression program of immune receptor and apoptotic signaling. This raises the question, whether EPIi or METABi with patients of rewired epigenetics and tumor metabolism have the ability to support the efficacy of IMMUNOi. Captivatingly, a metabolic enzyme, lactate dehydrogenase, central to the Warburg effect in cancer is a negative prognosticator for IMMUNOi response and predictive biomarker for overall survival of patients with malignant melanoma [115, 116]. Taken together, patients with somatic activation of EZH2 may benefit from treatment combinations that include inhibitors of EZH2  (Fig. 4c). Given a more than 60% frequency of genomic and non-genomic somatic activation of EZH2 in melanoma patients, this case of precision medicine might be more generalizable and synergy between epigenetic and immune checkpoint inhibition has a strong potential for a broader treatment regimen.
7 The ideal personalized strategy is specific but has wide coverage
A major concern of precision medicine approaches is the generalizability of identified somatic events and isolated case studies. Tumor heterogeneity and high background mutation rate in cancers like melanomas further impede one-dimensional disease management that can be expected to work for all patients. Comparisons to genomics databases like TCGA support the significance of the observed co-occurring signature of BRAF with epigenetic regulators (Fig. 4d) [117, 118]. EZH2, cAMP-responsive element binding protein 3 like 2 (CREB3L2, Gene ID: 64764), and KDM7A are not only significantly co-amplified due to their genomic proximity (p value below 0.001); their mutational signature shows co-occurrence as well [13, 85]. In addition, important epigenetic regulators with tumor suppressor function are lost in melanoma at the level of somatic copy number deletions or inactivating somatic mutations. Taken together, the observed precision medicine signature representative for any patient with rewired MAPK and epigenetic regulators is likely to be relevant to the majority of the melanoma cohort (229 of 287), taking all genomic, transcriptomic, and proteomic data into consideration (Fig. 4d).
8 Melanoma subtypes and predominance of MAPK-related signaling
9 Activation of the MAPK pathway by genomic and non-genomic mechanisms
Activation of BRAF alone by somatic mutation, amplification, transcriptional upregulation, or post-translational modification is present in more than 80% of the patients. In addition to BRAF(V600E) non-silent, polar replacements in the activator loop (p.D594G/H/N, p.G596D/R/S p. L597Q/R/S, p.T599TT, p.K601E/N/T), the glycine-rich ATP binding site (p.G466A/E/V, p.S467L, p.G469A/E/L/R/S/V), or the protein interaction surfaces of BRAF activate MAPK signaling (Fig. 5c). In the case of genomic MAPK activation (subtype I), the BRAF status as well as signature UV mutations provide insight into the molecular origin of melanoma. Knowledge of subtype IA vs IB is of importance for the choice of the drug regime, where BRAF(V600E) mutations were the prime target scaffold for small-molecule design [38, 125, 126]. Both CSD and non-CSD subtypes share genomic activation of core elements of the MAPK pathway. The remaining non-genomic MAPK subtype (also referred to as BRAF/NRAS/NF1 wild-type subtype) predominates in younger individuals with overall lower mutation burden and heterogeneous origin. However, at low frequency, non-genomic MAPK melanoma drivers are found in pathways of G protein-coupled receptors, metabolism, or epigenetic signaling (Fig. 5a). Overexpression of receptor tyrosine kinases platelet-derived growth factor receptor beta (PDGFRB, PDGFR, Gene ID: 5159) or MET proto-oncogene (MET, HGFR, Gene ID: 4233) following BRAF inhibition will reactivate mitogenic and survival pathways [52, 53, 127, 128]. A frequent observation in BRAF inhibitor resistance is coincidence with G protein-, RAS-, or PI3K-mediated reactivation of the MAPK pathway at the level of MAP2Ks or MAP3Ks. In addition to altered gene expression, other non-genomic mechanisms of regulation include promoter methylation, histone modifications, non-coding RNAs, posttranslational modification at the protein level, or metabolic feedback . Importantly, non-genomic MAPK drivers have the ability to bypass central MAPK molecules and activate a similar program of MAPK effectors, without genomic activation of core or upstream factors such as BRAF in the MAPK pathways.
10 Non-genomic MAPK subtype and oncogenic signaling in uveal melanoma
There is a striking similarity of the non-genomic MAPK subtype and oncogenic signaling in uveal melanoma. Uveal melanomas have less frequent somatic mutations and SCNAs in a much lower frequency than cutaneous melanoma. While BRAF and NRAS are usually of wild-type status , somatic mutations and SCNAs affecting G protein signaling are observed [130, 131]. However, the non-genomic MAPK program is heterogeneous and difficult to diagnose and treat, since similar mechanisms to MAPKi resistance might be utilized . In uveal melanoma, combined inhibition of MAP2K1 and AKT results in synergistic anticancer activity of G protein-mutant tumors. In contrast, BRAF inhibition of the same tumors can enhance mitogen-activated protein kinase 1 (MAPK1, ERK, Gene ID: 5594) signaling, emphasizing the importance of personalized, genotype-based approaches. The effector program common to genomic MAPK and non-genomic MAPK subtypes is illustrated by activation of the RAC1 and AKT signaling axis, as well as activation of the E2F family transcription factors governing cell cycle progression. Total mutation burden as well as the fraction of genome altered are elevated with loss of tumor suppressors. Tumor suppressors exemplify the close connection between UV-related CPD-mediated nucleotide transversion with age-related accumulated genomic damage present in CSD melanoma. However, strict mutual exclusivity of major melanoma tumor suppressors NF1, PTEN, TP53, or CDKN2A to non-CSD melanomas is not observed, possibly due to parallel and/or redundant signaling. Therefore, loss of tumor suppressors does not suggest clinically actionable stratification or justify independent subtypes in this framework.
11 Major signaling pathway alterations in melanoma
12 Signaling maps of melanoma and melanogenesis highlight predominant oncogenes and tumor suppressors
Melanocytes are derived from a neuroectodermal lineage providing them with a unique gene-expression signature and making them distinct from epithelial or non-epithelial cancers. Part of the melanocyte program is migration from the neural crest into ectoderm, differentiation, and clonal propagation of pigment-producing cells. Melanoma cells express neuroectodermal marker transmembrane receptors such as nerve growth factor receptor (NGFR, CD271, neurotrophin receptor, Gene ID: 4804), which has been found to be a marker for melanoma-initiating cells  (Fig. 6c). Melanogenesis and melanoma progression are interconnected by activation of wingless (WNT), melanocortin 1 receptor (MC1R, Gene ID: 4157), and melanogenesis-associated transcription factor (MITF, Gene ID: 4286) signaling. Not surprisingly, genomic profiles of melanoma and melanocytes overlap in transcriptional drivers of cellular mobility and proliferation, responsible for invasiveness and homing of melanoma [134, 135, 136, 137, 138] (Fig. 6d). Deregulation of melanogenesis can either contribute to dedifferentiation with loss of pigmentation comparable to a mesenchymal-epithelial transition, or elevated pigmentation and mitogenesis. Tyrosinase is essential for pigment synthesis in melanocytes and is an established antigen in melanoma. The roles of pigmentation in melanoma can be paradoxical: elevated tyrosinase expression can induce an auto-immune response leading to metastatic regression. Once tyrosinase-negative cells are able to escape this immune recognition, relapse and disease progression occur. Tumor suppressors are important safeguards of cells. The CDKN2A gene locus is frequently affected by copy number loss, non-sense mutations, and splicing aberration. Its two gene products, P14ARF and P16INK4A, control TP53 and RB transcriptional corepressor 1 (RB1, retinoblastoma protein 1, Gene ID: 5925) mediating cell cycle signaling [139, 140], respectively. Various genomic and non-genomic changes can lead to a deregulated cell cycle clock and apoptotic signaling (Figs. 6e and 7a–e). Inactivating mutations or promoter methylation of tumor suppressor RB1 and cell cycle inhibitors overwrite cell cycle checkpoints. Amplification and transcriptional upregulation of cyclins and cyclin-dependent kinases lead to RB1 phosphorylation and cell cycle progression. The tumor suppressor and pocket protein RB1 usually restricts the cell cycle progression by protecting and inhibiting the oncogenic E2F transcription factor family. Similarly, amplification and transcriptional upregulation of E2F transcription factors promote the cell cycle (Fig. 7f). Captivatingly, E2Fs are engaged in feedback loops by controlling cell cycle, anti-apoptotic survival pathways, and epigenetic regulators. E2F transcription factors including their main representative E2F1 are upstream regulators of the epigenetic polycomb complex around EZH2 constituting an important link to maintenance of the stem cell-like state of melanoma cells . In addition, EZH2 has the ability to interfere with apoptotic pathways and immune evasion by repressing tumor suppressors, immune, cytokine and chemokine receptors (Fig. 6e). Signaling maps in combination with precision medicine profiles of cancer patients provide rational insights in treatment options and highlight predominant hubs of oncogenes and tumor suppressors (Figs. 3, 4, 5, 6, and 7).
Melanoma precision medicine has significantly benefitted from large-scale sequencing efforts. Exome-wide and genome-wide sequencing initiated genomic biomarkers, targeted therapeutics, and encouraging clinical results. Collaborative, multiplatform genome sequencing approaches in cancer will be integrated into clinical practice in the near future. Molecular systems biology insights will impact prevention, diagnosis, and management of melanoma. Building a precision medicine framework is an investment in improved diagnostics and treatment protocols. Advanced molecular, high-throughput platforms fuel systems biology interpretation and enable novel genotype-phenotype associations in human melanoma. Cancer precision medicine still has to overcome challenges to promote the effective integration of genomic technology into clinical oncology practice. Melanoma is either characterized by frequent genomic alterations or genotypic heterogeneity. Therefore, acquired genomic precision data requires integration with cancer databases and clinical statistics. The objective is to distinguish between cancer drivers with clinically actionable targets or phenotypically neutral events, so that the treating precision medicine team can prioritize which clinical decisions should be pursued in order to provide cancer care that is personalized to the unique genome of the patient. Currently approved mono- and combination therapies are promising, and molecular insights from precision medicine have the ability to suggest orthogonal treatment targeting epigenetics and metabolism to overcome drug resistance and immune evasion.
F.V.F. is grateful for the support of grant CA154887 from the National Institutes of Health, National Cancer Institute. The research of the University of California Merced Systems Biology and Cancer Metabolism Laboratory is generously supported by CRCC CRN-17-427258, NSF, GCR, and HSRI program grants. This work is dedicated to my children, Leland Volker Filipp and Franziska Violet Filipp. You have made me stronger, better, and more fulfilled than I could have ever imagined. I love you to the moon and back.
Compliance with ethical standards
The study on precision medicine and cancer systems biology of malignant melanoma was carried out according to Institutional Review Board approval UCM13-0025 of the University of California Merced and as part of dbGap ID 5094 on somatic mutations in cancer and conducted in accordance with the Helsinki Declaration of 1975.
Conflict of interest
There is no conflict of interest.
- 3.Zhang, L., Huang, J., Yang, N., Greshock, J., Megraw, M. S., Giannakakis, A., et al. (2006). microRNAs exhibit high frequency genomic alterations in human cancer. Proceedings of the National Academy of Sciences of the United States of America, 103(24), 9136–9141. doi: 10.1073/pnas.0508889103.PubMedPubMedCentralCrossRefGoogle Scholar
- 16.T. C. G. A. Research Network (2012). Comprehensive molecular characterization of human colon and rectal cancer. Nature, 487(7407), 330–337. doi: 10.1038/nature11252.
- 17.T. C. G. A. Research Network. (2012). Comprehensive genomic characterization of squamous cell lung cancers. Nature, 489(7417), 519–525. doi: 10.1038/nature11404.
- 18.T. C. G. A. Research Network. (2012). Comprehensive molecular portraits of human breast tumours. Nature, 490(7418), 61–70. doi: 10.1038/nature11412.
- 23.T. C. G. A. Research Network (2015). Genomic classification of cutaneous melanoma. Cell, 161(7), 1681–1696. doi: 10.1016/j.cell.2015.05.044.
- 32.Natarajan, P., Gold, N. B., Bick, A. G., McLaughlin, H., Kraft, P., Rehm, H. L., et al. (2016). Aggregate penetrance of genomic variants for actionable disorders in European and African Americans. Science Translational Medicine, 8(364), 364ra151. doi: 10.1126/scitranslmed.aag2367.PubMedCrossRefGoogle Scholar
- 35.Juengst, E., McGowan, M. L., Fishman, J. R., & Settersten Jr., R. A. (2016). From “personalized” to “precision” medicine: the ethical and social implications of rhetorical reform in genomic medicine. The Hastings Center Report, 46(5), 21–33. doi: 10.1002/hast.614.PubMedPubMedCentralCrossRefGoogle Scholar
- 51.Hauschild, A., Grob, J. J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., et al. (2012). Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 380(9839), 358–365. doi: 10.1016/S0140-6736(12)60868-X.PubMedCrossRefGoogle Scholar
- 52.Krepler, C., Xiao, M., Sproesser, K., Brafford, P. A., Shannan, B., Beqiri, M., et al. (2016). Personalized preclinical trials in BRAF inhibitor-resistant patient-derived xenograft models identify second-line combination therapies. Clinical Cancer Research, 22(7), 1592–1602. doi: 10.1158/1078-0432.CCR-15-1762.PubMedCrossRefGoogle Scholar
- 53.Wagle, N., Van Allen, E. M., Treacy, D. J., Frederick, D. T., Cooper, Z. A., Taylor-Weiner, A., et al. (2014). MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discovery, 4(1), 61–68. doi: 10.1158/2159-8290.CD-13-0631.PubMedCrossRefGoogle Scholar
- 55.Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., et al. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences of the United States of America, 100(14), 8372–8377. doi: 10.1073/pnas.1533209100.PubMedPubMedCentralCrossRefGoogle Scholar
- 56.Yuan, J., Gnjatic, S., Li, H., Powel, S., Gallardo, H. F., Ritter, E., et al. (2008). CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proceedings of the National Academy of Sciences of the United States of America, 105(51), 20410–20415. doi: 10.1073/pnas.0810114105.PubMedPubMedCentralCrossRefGoogle Scholar
- 62.Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., et al. (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. The Lancet Oncology, 16(8), 908–918. doi: 10.1016/S1470-2045(15)00083-2.PubMedCrossRefGoogle Scholar
- 63.Chen, G., McQuade, J. L., Panka, D. J., Hudgens, C. W., Amin-Mansour, A., Mu, X. J., et al. (2016). Clinical, molecular, and immune analysis of dabrafenib-trametinib combination treatment for BRAF inhibitor-refractory metastatic melanoma: a phase 2 clinical trial. JAMA Oncology, 2(8), 1056–1064. doi: 10.1001/jamaoncol.2016.0509.PubMedPubMedCentralCrossRefGoogle Scholar
- 64.van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., et al. (2013). Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. Journal of Clinical Oncology, 31(32), e439–e442. doi: 10.1200/JCO.2012.47.7521.PubMedCrossRefGoogle Scholar
- 68.Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., et al. (2015). Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 348(6230), 124–128. doi: 10.1126/science.aaa1348.PubMedPubMedCentralCrossRefGoogle Scholar
- 74.Robbins, P. F., Lu, Y. C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., et al. (2013). Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nature Medicine, 19(6), 747–752. doi: 10.1038/nm.3161.PubMedPubMedCentralCrossRefGoogle Scholar
- 75.Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., et al. (2015). Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science, 348(6236), 803–808. doi: 10.1126/science.aaa3828.PubMedPubMedCentralCrossRefGoogle Scholar
- 81.Santos, G., Nikolov, S., Lai, X., Eberhardt, M., Dreyer, F. S., Paul, S., et al. (2016). Model-based genotype-phenotype mapping used to investigate gene signatures of immune sensitivity and resistance in melanoma micrometastasis. Scientific Reports, 6, 24967. doi: 10.1038/srep24967.PubMedPubMedCentralCrossRefGoogle Scholar
- 85.Tiffen, J., Wilson, S., Gallagher, S. J., Hersey, P., & Filipp, F. V. (2016). Somatic copy number amplification and Hyperactivating somatic mutations of EZH2 correlate with DNA methylation and drive epigenetic silencing of genes involved in tumor suppression and immune responses in melanoma. Neoplasia, 18(2), 121–132. doi: 10.1016/j.neo.2016.01.003.PubMedPubMedCentralCrossRefGoogle Scholar
- 86.Prior, F. W., Clark, K., Commean, P., Freymann, J., Jaffe, C., Kirby, J., et al. (2013). TCIA: an information resource to enable open science. Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2013, 1282–1285. doi: 10.1109/EMBC.2013.6609742.Google Scholar
- 87.Gutman, D. A., Cobb, J., Somanna, D., Park, Y., Wang, F., Kurc, T., et al. (2013). Cancer Digital Slide Archive: an informatics resource to support integrated in silico analysis of TCGA pathology data. Journal of the American Medical Informatics Association, 20(6), 1091–1098. doi: 10.1136/amiajnl-2012-001469.PubMedPubMedCentralCrossRefGoogle Scholar
- 89.Kamburov, A., Lawrence, M. S., Polak, P., Leshchiner, I., Lage, K., Golub, T. R., et al. (2015). Comprehensive assessment of cancer missense mutation clustering in protein structures. Proceedings of the National Academy of Sciences of the United States of America, 112(40), E5486–E5495. doi: 10.1073/pnas.1516373112.PubMedPubMedCentralCrossRefGoogle Scholar
- 96.Hamosh, A., Scott, A. F., Amberger, J., Valle, D., & McKusick, V. A. (2000). Online Mendelian Inheritance in Man (OMIM). Human Mutation, 15(1), 57–61. doi: 10.1002/(SICI)1098-1004(200001)15:1<57::AID-HUMU12>3.0.CO;2-G.PubMedCrossRefGoogle Scholar
- 100.Scott, D. A., Richardson, A. D., Filipp, F. V., Knutzen, C. A., Chiang, G. G., Ronai, Z. A., et al. (2011). Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. The Journal of Biological Chemistry, 286(49), 42626–42634. doi: 10.1074/jbc.M111.282046.PubMedPubMedCentralCrossRefGoogle Scholar
- 101.Filipp, F. V., Scott, D. A., Ronai, Z. A., Osterman, A. L., & Smith, J. W. (2012). Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigment Cell & Melanoma Research, 25(3), 375–383. doi: 10.1111/j.1755-148X.2012.00989.x.CrossRefGoogle Scholar
- 103.Wilson, S., Qi, J., & Filipp, F. V. (2016). Refinement of the androgen response element based on ChIP-Seq in androgen-insensitive and androgen-responsive prostate cancer cell lines. Scientific Reports, 6, 32611. doi: 10.1038/srep32611.
- 104.Wilson, S., Fan, L., Sahgal, N., Qi, J., & Filipp, F. V. (2017). The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells. Oncotarget, 8. doi: 10.18632/oncotarget.15681.
- 105.Struys, E. A., Salomons, G. S., Achouri, Y., Van Schaftingen, E., Grosso, S., Craigen, W. J., et al. (2005). Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria. American Journal of Human Genetics, 76(2), 358–360. doi: 10.1086/427890.PubMedCrossRefGoogle Scholar
- 108.Filipp, F. V. (2017). Crosstalk between epigenetics and metabolism—Yin and Yang of histone demethylases and methyl-transferases in cancer. Briefings in Functional Genomics, 16. doi: 10.1093/bfgp/elx001.
- 109.Tiffen, J. C., Gunatilake, D., Gallagher, S. J., Gowrishankar, K., Heinemann, A., Cullinane, C., et al. (2015). Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes. Oncotarget, 6(29), 27023–27036. doi: 10.18632/oncotarget.4809.PubMedPubMedCentralCrossRefGoogle Scholar
- 110.Mao, P., Smerdon, M. J., Roberts, S. A., & Wyrick, J. J. (2016). Chromosomal landscape of UV damage formation and repair at single-nucleotide resolution. Proceedings of the National Academy of Sciences of the United States of America, 113(32), 9057–9062. doi: 10.1073/pnas.1606667113.PubMedPubMedCentralCrossRefGoogle Scholar
- 115.Kelderman, S., Heemskerk, B., van Tinteren, H., van den Brom, R. R., Hospers, G. A., van den Eertwegh, A. J., et al. (2014). Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunology, Immunotherapy, 63(5), 449–458. doi: 10.1007/s00262-014-1528-9.PubMedGoogle Scholar
- 123.Premi, S., Wallisch, S., Mano, C. M., Weiner, A. B., Bacchiocchi, A., Wakamatsu, K., et al. (2015). Photochemistry. Chemiexcitation of melanin derivatives induces DNA photoproducts long after UV exposure. Science, 347(6224), 842–847. doi: 10.1126/science.1256022.PubMedPubMedCentralCrossRefGoogle Scholar
- 124.Abdel-Malek, Z. A., Swope, V. B., Starner, R. J., Koikov, L., Cassidy, P., & Leachman, S. (2014). Melanocortins and the melanocortin 1 receptor, moving translationally towards melanoma prevention. Archives of Biochemistry and Biophysics, 563, 4–12. doi: 10.1016/j.abb.2014.07.002.PubMedCrossRefGoogle Scholar
- 132.Mitsiades, N., Chew, S. A., He, B., Riechardt, A. I., Karadedou, T., Kotoula, V., et al. (2011). Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. Investigative Ophthalmology & Visual Science, 52(10), 7248–7255. doi: 10.1167/iovs.11-7398.CrossRefGoogle Scholar
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.